Another advantage to an immediate trial is having a better sense of the scale/scope downsides. Some people are going to miss the booster, and require allocation of (limited) resources to track down. So who and when? A trial would help shed light on that.
We are not spreading a dangerous idea, we’re taking one with a real upside and trying to put it on a solid path. Do you notice how many prominent politicians had been advocating for this? It’s not a world where we can somehow keep things quiet—or control them without being there.
-
-
The question I’ve asked is whether boosting this idea in the NYT and elsewhere as opposed to working behind the scenes to develop a trial has potential downsides. All I hear from you and Michael is that this approach has no risks.
-
The project of vaccinating hundreds of millions of people is so complex, as you noted, that there is a huge upside to a single dose approach. But that same complexity suggests that if people lose confidence in a needed booster (if needed) then that might be bad.
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.